Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 9/20 | 0.35 |
| ▸ | CA2 | P00918 | 9/20 | 0.35 |
| ▸ | CA9 | Q16790 | 9/20 | 0.35 |
| ▸ | CA12 | O43570 | 8/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367361 | 0.86 | CA9 (0.40) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL16367358 | 0.81 | CA9 (0.40) | CA1CA2CA9CA12CA14 | |
| SCHEMBL16367394 | 0.79 | ADORA3 (0.43) | ALDH1A1 | |
| SCHEMBL16367311 | 0.76 | LMNA (0.40) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL16367332 | 0.75 | LMNA (0.39) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL16367416 | 0.74 | LMNA (0.36) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL17366441 | 0.70 | LMNA (0.54) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL11784305 | 0.70 | CA1 (0.62) | LMNATHRBSMN1; SMN2HIF1ACA1 | |
| SCHEMBL16367318 | 0.69 | ADORA3 (0.43) | TP53HIF1A | |
| SCHEMBL16367316 | 0.69 | ADORA3 (0.43) | TP53HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | LMNA 4469/4885ALDH1A1 140/4885TP53 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.